scAAV ShH10-CAG-GFP

Name: scAAV ShH10-CAG-GFP
SKU: AAV00420Z
Rating: 4.0 (1 reviews)

Cat.No. : AAV00420Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype: AAV serotype ShH10 Storage: -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No.	AAV00420Z
Description	Premade self-complementary AAV particles in serotype ShH10 (scAAV ShH10) express GFP reporter gene from the CAG promoter.
Serotype	AAV serotype ShH10
Target Gene	GFP
Titer	Varies lot by lot, typically ≥1x10^12 GC/mL
Size	Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage	Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping	Frozen on dry ice

Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin	Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity	AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility	The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility	Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids	Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.

Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Wild-type AAV is a small virus of the Parvoviridae family, 4.7 kb in size, and is a linear single-stranded DNA (ssDNA). They are composed of an icosahedral protein capsid containing three subunits (VP1, VP2, and VP3) in a total of 60 copies in a 1:1:10 ratio (VP1:VP2:VP3). Its genome contains a rep gene encoding four proteins required for viral replication; a cap gene encoding three capsid subunits through alternative splicing and translation from different start codons; and a gene encoding assembly activation protein (AAP), which promotes virion assembly. These genes are flanked by inverted terminal repeats (ITRs), which are required to direct genome replication and packaging. For therapeutic use, the rep and cap genes are removed and replaced with an expression cassette containing a therapeutic transgene under the control of a promoter and flanked by AAV ITR sequences, resulting in recombinant adeno-associated virus (rAAV). There are hundreds of variants of AAV, including 11 natural serotypes: AAV 1-11.

Recombinant adeno-associated virus (AAV)-mediated therapeutic gene transfer is an effective and safe tool for the treatment of chronic pain. Activated glial cells play an important role in pain pathophysiology and are promising targets for therapeutic intervention. However, the natural tropism of AAV vectors results in gene transfer mainly to neurons, while glial cells in the central nervous system (CNS) and peripheral nervous system (PNS) are resistant to AAV transduction. AAVshH10 is a recently designed novel variant similar to AAV6 that can efficiently and selectively transduce Muller glial cells in the retina. Titer-matched AAVshH10 and original AAV6 were injected into dorsal root ganglia (DRG) and spinal cord (SC) of adult rats. The results showed that injection of AAVshH10 into DRG and SC showed similar results to its parental AAV6, with both being able to effectively transduce all sensory neuron subsets in DRG or neurons in SC, and no significant transduction of glial cell populations in both sites.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

First Name

Country *

Email *

Customer Reviews

Invaluable tool

I've been using Creative Biogene's scAAV ShH10-CAG-GFP for neuronal studies, and the results are exceptional. The expression of GFP is bright and stable, greatly facilitating our imaging and analysis.

United States

04/17/2025

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

First Name

Country *

Email *

scAAV ShH10-CAG-GFP

AAV Particle Information

Quality Control

Background

Publications

Q & A

Customer Reviews

Invaluable tool

Related Services